Patent litigation and regulatory disputes work is at the heart of Schertenleib’s healthcare and life sciences practice, with the team acting for clients across the pharmaceutical, medical devices and cosmetics industries. Spearheading the team, Denis Schertenleib excels in multinational litigation, in particular IP matters. Ombeline Degèze-Péchade’s extensive expertise encompasses complex regulatory frameworks and covert market strategies, while Marc Lauzeral is a name to note for cross-border patent and SPC disputes.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Sector knowledge
Testimonials
Collated independently by Legal 500 research team.
- ‘The Schertenleib team consists of excellently skilled lawyers who are quick thinking with a lot of experience in the pharmaceutical and life sciences industries.'
- 'The team have a deep and thorough understanding of the regulatory background and are able to provide in-depth analysis and legal advice that truly takes all relevant factors into account. They are diligent, committed, extremely knowledgeable and responsive. Absolutely recommended!’
- ‘Ombeline Degèze-Péchade is extremely responsive and provides brilliant advice due to her extensive knowledge and experience. Ombeline and the Schertenleib law firm are definitely a go-to address for all healthcare and life sciences related questions.’
- ‘A competent, attentive, and adaptable team provides genuine support to the client, taking into account their specific needs and constraints.’
- ‘The team are tenacious and will explore every avenue for the client. Denis Schertenleib and Marc Lauzeral in particular are totally focussed on achieving great outcomes for clients and never give up.’
Key clients
- Recor Medical Inc. & Otsuka Medical Device
- Viatris
- Neuraxpharm
- Sandoz
- Zentiva
- Filorga
- Fill-Med
- Bio-Rad
Work highlights
Represented Sandoz in invalidity proceedings against Bayer’s patent relating to Rivaroxaban, one of Bayer’s blockbuster drugs and a strategic product for the client’s European portfolio.
Represented Viatris in litigation initiated by Biogen before the Paris Court of First Instance, concerning dimethyl fumarate (DMF)—one of Biogen’s blockbuster drugs used in the treatment of multiple sclerosis.
Advised a major Korean biopharmaceutical company on key regulatory and competition law issues under French and EU law in connection with the launch of a leading biosimilar.
Practice head
Denis Schertenleib
Other key lawyers
Marc Lauzeral; Ombeline Degèze-Péchade